...Imprimis exercised its option to convert its non-exclusive, U.S. license to Urigen’s Hep-Lido-A to an exclusive...
...formulation of heparin and alkalinized lidocaine is marketed to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Urigen...
...dose or 15-20% of Imprimis’ net sales. Imprimis received the non-exclusive right in October 2014. Urigen Pharmaceuticals Inc....

...Urigen Pharmaceuticals Inc. , North Brunswick, N.J. Business: Genitourinary Date announced: 2015-05-04 Type: IPO Note: Urigen...

...Valeritas Inc. 2/12/15 $75M Mkt (device) Klox Technologies Inc. 2/11/15 Up to $75M Development (device) Urigen Pharmaceuticals Inc....

...2015-02-11 Type: IPO To be raised: Up to $25 million Shares: TBD Price: TBD Note: Urigen...

...Urigen announced that the SEC decided to revoke the company's registered securities. Urigen has been delinquent...
...in its SEC filings since failing to timely file its Form 10-K in September 2010. Urigen...
...appeal the decision, which is expected to become final on or around Oct. 10. *** Urigen Pharmaceuticals Inc....

...at $0.10. The investor also receives five-year warrants to purchase 5.5 million shares a $0.13. Urigen Pharmaceuticals Inc....

...2009 deal that gave Oceana a right of first refusal to license all indications of Urigen's...
...be approved by FDA. Under the terms of the original agreement, Oceana was to assist Urigen...
...and pay up to $50,000 in fees to Urigen's consultants in connection with the meeting. Urigen...